Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacnotuzumab - Novartis Oncology

Next Previous
Drug Profile

Lacnotuzumab - Novartis Oncology

Alternative Names: Anti-M-CSF-antibody; MCS-110

Latest Information Update: 23 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology; Seoul National University Hospital
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone metastases; Gastric cancer; Giant cell tumour of tendon sheath; Malignant melanoma; Pigmented villonodular synovitis; Prostate cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 23 Oct 2024 Discontinued - Phase-I for Triple-negative-breast-cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Spain, Japan, Japan, Hong Kong, USA, Israel, Netherlands, Italy, Australia (IV) prior to October 2024 (Novartis pipeline, October 2024)
  • 23 Oct 2024 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) prior to October 2024 (Novartis pipeline, October 2024)
  • 23 Oct 2024 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy, Switzerland, Belgium, France, USA, Japan, Hong Kong (Parenteral) prior to October 2024 (Novartis pipeline, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top